New drug APL-9796 tested for lung blood pressure disorder
NCT ID NCT06846554
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an experimental drug called APL-9796 in 48 adults with pulmonary hypertension (high blood pressure in the lungs). The study aims to see if the drug is safe, tolerable, and effective. Participants receive injections under the skin, and researchers monitor side effects, heart function, and walking ability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APL-9796 (an experimental drug given as injections under the skin)
What this could lead to
If successful, this could point toward a new treatment option for pulmonary hypertension, potentially improving heart and lung function.
What could go wrong
This is an early Phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or prove no better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Golden Jubilee Hospital
RECRUITINGClydebank, United Kingdom
-
Hammersmith/Imperial Hospital
RECRUITINGLondon, London, W12 0HS, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Brompton Hospital
RECRUITINGLondon, United Kingdom
-
Royal Papworth Hospital
RECRUITINGCambridge, United Kingdom
-
Royal United Hospital Bath
RECRUITINGBath, United Kingdom
-
Sheffield Teaching Hospitals
RECRUITINGSheffield, United Kingdom